Active Substance: Vancomycin.
Overview
Welcome to Dwaey, specifically on VANCOMICINA AZEVEDOS 500 mg page.
This medicine contains an important and useful components, as it consists of
Vancomycinis available in the market in concentration
Vancomycin
Patient w/ allergic reaction to teicoplanin, previous hearing loss, inflammatory bowel disease. Renal impairment. Elderly. Pregnancy and lactation. Monitoring Parameters Determine regularly serial tests of auditory function and serum or blood vancomycin concentrations during treatment. Periodic urinalysis and renal function tests. Monitor leukocyte count in prolonged therapy. Lactation: Drug enters breast milk; not recommended
Septicaemia, Soft tissue infections, Osteomyelitis, Enterocolitis, Colitis, Serious staphylococcal or other Gm +ve infections, Bacterial endocarditis
Hypersensitivity to the drug; history of impaired hearing; IM administration.
>10% Erythematous rash on face and upper body (red neck or red man syndrome; related to infusion rate),Hypotension accompanied by flushing 1-10% Chills,Drug fever,Eosinophilia,Rash,Reversible neutropenia,Phlebitis <1% Nephrotoxicity,Ototoxicity (especially with large doses),Stevens-Johnson syndrome,Thrombocytopenia,Vasculitis Potentially Fatal: Stevens-Johnson syndrome; toxic epidermal necrolysis, blood dyscrasias such as neutropenia or thrombocytopenia.
3
Vancomycin binds tightly to D-alanyl-D-alanine portion cell wall precursor causing blockage of glycopeptide polymerisation which produces immediate inhibition of cell wall synthesis and secondary damage to the cytoplasmic membrane.
General anaesth may enhance the adverse effects of vancomycin. Increased risk of ototoxicity and nephrotoxicity w/ aminoglycosides, polymyxins, ciclosporin, cisplatin and loop diuretics. Increased potential of neuromuscular blockade w/ suxamethonium or vecuronium.
Information not available